Yap, TE; Normando, EM; Cordeiro, MF; (2018) Redefining clinical outcomes and endpoints in glaucoma. Expert Review of Ophthalmology , 13 (2) pp. 113-127. 10.1080/17469899.2018.1465820.

Preview

Text Cordeiro_Yap Revision MS.pdf - Accepted Version Download (556kB) | Preview

Abstract

Introduction: Increasing life expectancy and ageing populations across the world are causing the number of glaucoma patients to rise dramatically. With longer lifespans also comes the need to improve the timeframe and accuracy with which we can diagnose, monitor and treat patients, ensuring longevity of vision contributes to a meaningful quality of life. Current markers used in glaucoma practice are in many cases suboptimal in their ability to accurately identify glaucomatous damage in time to prevent irreversible optic neuropathy. // Areas covered: This review summarises the important properties of successful biomarkers and surrogates, and relates this to how intraocular pressure, visual field testing, and imaging have been refined to improve early diagnosis and progression analysis of glaucoma patients. Secondly, we discuss newer concepts in imaging, genetics, and quality of life measures which may provide biomarkers and surrogate endpoints with which to develop novel treatments in the future. // Expert commentary: We summarise the key relevant points in glaucoma research, and the current techniques being trialled that are most likely to lead to valuable biomarkers for the future.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item